Spectrum Pharmaceuticals, Inc. Executes $6 Million License and Supply Agreements With Servier Canada, Inc.

Spectrum Pharmaceuticals, Inc.

Represented Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) in the execution of license and supply agreements in connection with its strategic partnership with Servier Canada, Inc. for the out-license of commercialization rights to ZEVALIN®, FOLOTYN®, BELEODAQ®, and MARQIBO® in Canada. Spectrum will receive $6 million in upfront payments, development milestone payments if/when achieved, and a high single-digit royalty on their sales of these products in Canada.

Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in Hematology and Oncology.

The Newport Beach-based team representing Spectrum included Marc Alcser and Azad Virk.